ArticleAnnals of intensive care2026
Innate immune response in COVID-19 pneumonia during the pandemic: a prospective cohort study.
Article in Annals of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dysregulated innate immunity contributes to COVID-19 severity, but its evolution over the periods of the pandemic is undefined. The aim of the study was to compare ex vivo innate immune responses in COVID-19 and non-COVID-19 community-acquired pneumonia (CAP) and assess associations with pandemic period, severe respiratory failure (SRF), mortality, and circulating microRNA patterns. Methods: In this prospective cohort study conducted at 2 tertiary hospitals in Athens, Greece, 102 hospitalized patients with COVID-19 pneumonia and 28 with non-COVID-19 community-acquired pneumonia were enrolled. Peripheral blood mononuclear cells were isolated during the first 24 hours before any immune intervention other than dexamethasone and stimulated for cytokine production. SRF was defined as a PaO₂/FiO₂ ratio <150 mmHg necessitating invasive or non-invasive ventilation. Exploratory serum microRNA sequencing was performed in a small subset. Results: On Day 1, release of TNFα and IL-6 was higher by the PBMCs of patients with COVID-19 pneumonia than non-COVID-19 CAP; the opposite was found for IL-1RA. Patients infected by the Omicron variant had higher production of TNFα and lower of IL-6. Using multivariate logistic regression analysis, it was confirmed that over-time decrease of the production of IL-6 by the PBMCs of patients with COVID-19 was a risk factor for progression into SRF and 28-day mortality. Conclusion: COVID-19 pneumonia and non-COVID-19 CAP exhibited distinct patterns of ex vivo PBMC responsiveness, characterized by higher TNF-α and IL-6 production in COVID-19. Functional cytokine responses also varied across pandemic periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.